Aktiechat - investeringstips
Aktiesnakken
TESLA
Genmab
NOVO
Bavarian Nordic
Zealand Pharma
Biotek-snakken
Shipping
Ennogie
Amerikanske aktier
Grønne Aktier
AMBU
Pharma
EL-BILER
Medico
BITCOIN
Vestas
ExpreS2ion
Chemometec
AI/Kunstig intelligens
Banker og Finans
GN Store Nord
Hansa Biopharma
OLIE OG GAS
Laks
Gubra
Krypto
11/5 16:09 af bibob |
Mr Winkel. Can you tell us the % of royalty you get from Teprutumumab. ?
| |
11/5 16:09 af Jan Van de Winkel |
future milestones could be triggered by clinical progress in daratumumab development as well as sales milestones.
| |
11/5 16:09 af Jan Van de Winkel |
The first milestone has just been achieved with the approval of daratumumab in Europe in second line MM (48 mn USD)....approx. 325 mn DKK...
| |
11/5 16:08 af Helge Larsen/PI-redaktør |
Bikube:
“800 million are expected in milestones. What events trigger these”?
| |
11/5 16:07 af Jan Van de Winkel |
the most significant tier, is that when sales exceed 3 bn USD, the royalty rate to Genmab will be 20%.
| |
11/5 16:07 af Jan Van de Winkel |
Current royalty is at 12 percent royalty tranche and we expect to step up one tier this year....
| |
11/5 16:06 af kkjoel |
Reg. dara royalty-levels: will you down the line, as the various thresholds are exceeded, inform the marked THAT they were exceeded and HOW MUCH the next royalty-%-step is? Or are we for ever destined to guess (which probably WILL come v close to facts).. based on JnJ turnover, approximate dollar-exchange rates, and GENs royalty-income?
| |
11/5 16:05 af Jan Van de Winkel |
Expenses 1 bn DKK leading to operating Income of 1 bn DKK, cash greater than 4.5 bn DKK.
| |
11/5 16:05 af Jan Van de Winkel |
Revenue guidance for 2017 is around 2 bn DKK....
| |
11/5 16:04 af Helge Larsen/PI-redaktør |
Can you tell us about your guiding for 2017?
| |
11/5 16:04 af Jan Van de Winkel |
and approval in important second line MM in Europe, and 48 mn USD milestone.
| |
11/5 16:03 af Jan Van de Winkel |
Exciting new trials BMS Opdivo, Tecentriq NSCLC, RRMM Dara + POM + d (Apollo), and the start of the Amgen RRMM Dara plus Krypolis + d....
| |
11/5 16:02 af Jan Van de Winkel |
up 28 percent to Q4 2016. Launched in 18 EU countries and US...
| |
11/5 16:02 af Jan Van de Winkel |
DARZALEX Janssen net sales 255 mn USD....
| |
11/5 16:01 af Jan Van de Winkel |
cash position 4.8 bn DKK....a great start to the year. Important events ...
| |
11/5 16:01 af Jan Van de Winkel |
revenue growth exceeded expense increase equaling an increase in operating income of 30 mn DKK to 46 mn DKK for Q1....
| |
11/5 16:00 af Jan Van de Winkel |
expenses up 33 percent, driven by the investment in our pipeline of products....
| |
11/5 16:00 af Jan Van de Winkel |
Revenues up 48 percent driven by DARZALEX royalty income....
| |
11/5 16:00 af Jan Van de Winkel |
David will start with the financials....
| |
11/5 16:00 af Helge Larsen/PI-redaktør |
Great. First of all let me just congratulate on the great results for Q1 . Can you give us a short-term update on key figures and important events in Q1?
| |
11/5 15:59 af Jan Van de Winkel |
We are eager to go!
| |
11/5 15:59 af Helge Larsen/PI-redaktør |
Jan van de Winkel and David Eatwell. Welcome to Q & A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
| |
11/5 15:58 af Helge Larsen/PI-redaktør |
:-)
| |
11/5 15:57 af Jan Van de Winkel |
yes, we are here. Nice to talk to you.
| |
| ||
11/5 15:56 af Helge Larsen/PI-redaktør |
Jan and David. Are you online?
|